2-Fluoro-5-(trifluoromethoxy)benzoic acid | CAS:886497-85-4

We serve 2-Fluoro-5-(trifluoromethoxy)benzoic acid CAS:886497-85-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Fluoro-5-(trifluoromethoxy)benzoic acid

Chemical Name:2-Fluoro-5-(trifluoromethoxy)benzoic acid
CAS.NO:886497-85-4
Synonyms:2-Fluoro-5-(trifluoromethoxy)benzoic acid
2-FLUORO-5-(TRIFLUOROMETHOXY)BENZOIC ACID
Molecular Formula:C8H4F4O3
Molecular Weight:224.10900
 
Physical and Chemical Properties:
Density:1.529
Boiling point:251.9ºC
Flash point:106.1ºC
Index of Refraction:1.462
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Fluoro-5-(trifluoromethoxy)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-FLUORO-5-(TRIFLUOROMETHOXY)BENZOIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Fluoro-5-(trifluoromethoxy)benzoic acid Use and application,2-Fluoro-5-(trifluoromethoxy)benzoic acid technical grade,usp/ep/jp grade.


Related News: TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.Dimethylcarbamoyl chloride manufacturer TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.(S)-3-Amino-3-phenylpropionic acid supplier At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.1-Chlorobutane vendor As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.